We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: gemtuzumab ozogamicin
MedXY News
EnglishTag

gemtuzumab ozogamicin

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Navigating Therapeutic Approaches in Pediatric Relapsed Acute Myeloid Leukemia: Current Trends and Comparative Outcomes
Hematology-Oncologypediatric AMLre-induction therapy

Navigating Therapeutic Approaches in Pediatric Relapsed Acute Myeloid Leukemia: Current Trends and Comparative Outcomes

By MedXY|Sep 3, 2026

This article reviews the variability and comparative effectiveness of re-induction treatments in pediatric relapsed AML, highlighting the role of gemtuzumab ozogamicin and chemotherapy backbones in improving remission rates but not overall

DAGO2 (daunorubicin+cytarabine+fractionated gemtuzumab) outperforms CPX‑351 in older adults with non‑adverse‑risk AML: insights from NCRI AML18
Hematology-Oncologyacute myeloid leukemia
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
CPX-351

DAGO2 (daunorubicin+cytarabine+fractionated gemtuzumab) outperforms CPX‑351 in older adults with non‑adverse‑risk AML: insights from NCRI AML18

By MedXY|Nov 15, 2025

In NCRI AML18 (n=439, median age 68), DAGO2 produced higher early CR/MRD‑negative rates and superior 3‑year EFS and OS versus CPX‑351 in older adults without adverse‑risk cytogenetics; survival differences persisted across key subgroups inc

Sustained Remission in Acute Promyelocytic Leukemia with ATO-ATRA and Gemtuzumab Ozogamicin: Long-Term Phase 2 Outcomes
Clinical Updatesgemtuzumab ozogamicin

Sustained Remission in Acute Promyelocytic Leukemia with ATO-ATRA and Gemtuzumab Ozogamicin: Long-Term Phase 2 Outcomes

By MedXY|Oct 7, 2025

A phase 2 study shows that combining all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin yields a 94% cure rate in acute promyelocytic leukemia with favorable safety over five years.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities